Latest USP Initiatives: Monographs, General Chapters, and Compounding

Size: px
Start display at page:

Download "Latest USP Initiatives: Monographs, General Chapters, and Compounding"

Transcription

1 Latest USP Initiatives: Monographs, General Chapters, and Compounding Jim Ponto, MS, RPh, BCNP

2 Disclosures Volunteer member on several USP Expert Committees and Expert Panels associated with radiopharmaceutical General Chapters and drug monographs This presentation is not endorsed by the USP, nor does it represent the views or opinions of the USP

3 Topics Background Issues with radiopharmaceutical monographs New format for radiopharmaceutical monographs Recent activities general chapters Radiopharmaceutical compounding

4 Background USP is a non-governmental agency that provides standards of identity, strength, quality, and purity of medications, excipients, and dietary supplements These standards are described in General Chapters (common tests and assays, methods, information) and in Monographs for individual drug substances and drug products (specific tests and acceptable limits) Typically, monographs are created only after FDA approval of drug product

5 Background (cont d) Development and revision of monographs are assigned to one of several Expert Committees (ECs) ECs consist of volunteers with expertise in a given area and are supported by USP scientific staff For the cycle, radiopharmaceuticals are assigned to Chemical Medicines Monographs 4 Expert Committee (CHM4 EC) Expert Panels (EPs) may be created to assist the EC when additional expertise is needed

6 Typical Creation of a Monograph A sponsor (typically the manufacturer) provides draft standards and supporting analytical data USP s scientific staff and volunteer experts review this input, conduct analytical testing in USP labs if necessary, and develop a proposed monograph The proposed monograph is published in Pharmacopeial Forum (PF) for public review and comment

7 Typical Creation of a Monograph (cont d) The proposed monograph is revised, as appropriate, based on public comments and then voted upon by the assigned Expert Committee The final monograph is published as official text in the USP-NF Revisions to existing monographs follow a similar process, but may undergo an accelerated process in certain circumstances

8 Issues with Radiopharmaceutical Monographs Nearly all radiopharmaceutical monographs need to be modernized to the new USP format and style Some monographs, especially those for older drugs and PET drugs, were developed in the absence of sponsors supporting data and prior to FDA approval USP labs are not licensed to handle radioactive materials, so typical testing cannot be performed to verify methods Reference standards do not exist for radioactive active ingredients

9 Issues with Radiopharmaceutical Monographs Many recently marketed radiopharmaceuticals do not yet have a monograph (the innovator is often reluctant to share proprietary information prior to generic competition) Monographs don t exist for marketed nonradioactive kits (e.g., DOTATATE kit)

10 Radiopharmaceutical Expert Panel Established in early 2016 under CHM4 EC Members: Corinne Bensimon David Pipes Jonathan Fitzsimmons Jim Ponto* Umesh Gangadharmath Ravi Ravichandran Ravi Kasliwal Kara Weatherman Thijs Kroon Martin Williamson* Adrian Nunn Steve Zigler* * Member CHM4 EC USP staff FDA representative

11 Initial Tasks Compile list of radiopharmaceutical monographs (N=75 current and pending) Prioritize tasks start with low-hanging fruit Review each radiopharmaceutical for marketing status in U.S. and other countries Recommend deletion of monographs for radiopharmaceuticals that are no longer relevant Each will be published in PF for public comment before removal Identify sponsors for monographs to be maintained and revised

12 Standard Monograph Format and Style: Radiopharmaceuticals Don t Fit Well USP guideline for submission of monographs al_medicines_rfr_guideline_-28apr16.pdf Some test methods for pharmacologic drug masses may not be appropriate for radiopharmaceuticals e.g., infrared/ultraviolet spectroscopy, liquid chromatography, gas chromatography Certain tests for radiopharmaceuticals are not described in this guideline e.g., radioactivity, radionuclidic purity, radiochemical purity

13 Modified Monograph Format and Style for Radiopharmaceuticals TITLE (e.g., Fludeoxyglucose F 18 Injection) DEFINITION Chemical information (e.g., chemical name) Other important characteristics (e.g., sterile) Amount (e.g., NLT x % and NMT x % of the labeled amount expressed in MBq (mci)/ml at the time of calibration) Added substances (e.g., may contain buffering agents, preservatives, stabilizing agents or sodium chloride) Specific activity (e.g., does not contain added carrier)

14 Modified Monograph Format and Style for Radiopharmaceuticals (cont d) IDENTIFICATION Radionuclidic Identity (cite <821>) Analysis (e.g., determine half-life or emission energy spectrum) Acceptance Criteria (e.g., half life is x y min; major photopeak energy is x KeV) Radiochemical Identity Analysis (e.g., comparison to chemical standard) Acceptance Criteria (e.g., NLT x % and NMT x %)

15 Modified Monograph Format and Style for Radiopharmaceuticals (cont d) ASSAY (cite <821>) Radioactivity Concentration (Strength) Analysis (e.g., determine MBq (mci)/ml) Acceptance Criteria (e.g., x % - y % at the time indicated on the label)

16 PURITY Modified Monograph Format and Style for Radiopharmaceuticals (cont d) Radionuclidic Purity (cite <821>) Analysis (e.g., collect emission energy spectrum and determine amount of each radionuclide, decay-correct to expiration time) Acceptance Criteria (e.g., NLT x % corresponds to the intended radionuclide) Radiochemical Purity Analysis (e.g., radiochromatography method) Acceptance Criteria (e.g., NLT x % )

17 Modified Monograph Format and Style for Radiopharmaceuticals (cont d) IMPURITIES Radionuclidic Impurities (cite <821>) Analysis (e.g., collect emission energy spectrum and determine amount of each radionuclide, decay-correct to expiration time) Acceptance Criteria (e.g., NMT x % of the radioactivity decay-corrected to time of expiration) Radiochemical Impurities Analysis (e.g., radiochromatography method) Acceptance Criteria (e.g., NMT x % )

18 Modified Monograph Format and Style for Radiopharmaceuticals (cont d) IMPURITIES (cont d) [Specific Identified Chemical Impurities] (e.g., related compounds that have a Reference Standard; residual solvents such as acetonitrile and ethanol) Analysis (e.g., chromatography method) Acceptance Criteria (e.g., NMT x microgram/ml; or NMT x %)

19 Modified Monograph Format and Style for Radiopharmaceuticals (cont d) Specific Tests Appearance (e.g., clear, colorless, free from visible particulates) ph (e.g., ph is x - y using short-range ph indicator paper) Bacterial Endotoxins Test (cite <85>) (e.g., NMT 175/V USP endotoxin units/ml where V is the maximum administered total dose in ml at the expiration time) Sterility Test (cite <71>) (state exceptions such as sample size or time delay before starting the test)

20 Modified Monograph Format and Style for Radiopharmaceuticals (cont d) Additional Requirements Packaging and Storage (e.g., single-dose or multiple-dose vial; adequately shielded; store at controlled room temperature) Labeling (e.g., date and time of calibration; radioactivity concentration in MBq (mci)/ml at calibration; total volume or total radioactivity at calibration; expiration date and time; name and quantity of any added preservative or stabilizer; make dosage calculations with correction for radioactive decay; the radionuclide s half-life; Caution Radioactive Material ; do not use if cloudy or if it contains visible particulate matter)

21 Modified Monograph Format and Style for Radiopharmaceuticals (cont d) USP Reference Standards (cite <11>) List (e.g., drug substance RS; drug-related compound RS)

22 First Monographs Revised Fludeoxyglucose F 18 Injection Ammonia N 13 Injection Proposed revisions of both monographs recently published in Pharmacopeial Forum PF 43(3) May-Jun 2017 Comment period ends July 31, 2017

23 Summary - Monographs Revising radiopharmaceutical monographs is a slow process, but a foundation has been laid to allow progress Need: sponsors for individual radiopharmaceutical products, especially for supporting documentation of analytical methods and results Need: public comment on proposed new and revised monographs published in PF

24 General Chapters In the past year, finalization and inclusion in USP 40: <821> Radioactivity (USP 15, rev USP 19; complete rewrite) <1821> Radioactivity Theory and Practice (new informational chapter) <1015> Automated Radiochemical Synthesis Apparatus (USP 29; delete in USP 40) <1823> Positron Emission Tomography Drugs -Information (new informational chapter) In Process: <823> Positron Emission Tomography Drugs for Compounding, Investigational, and Research Uses (USP 23, rev USP 35; re-formatted for style, no change in content)

25 Radiopharmaceutical Compounding <795> Pharmaceutical Compounding Nonsterile Preparations - does not apply to radiopharmaceuticals <797> Pharmaceutical Compounding Sterile Preparations - contains a short section on radiopharmaceuticals but lacks sufficient details to fully elucidate important differences for radiopharmaceuticals

26 Radiopharmaceutical Compounding in PET Dispensing of doses from a manufactured product Dilution of manufactured product prior to dispensing (e.g., FDG) Preparation on Ga-68 DOTATATE Perhaps other activities in the future

27 Compounding of Radiopharmaceuticals Similar to sterile compounding of conventional drugs e.g., aseptic practices, environmental facilities Also similar to hazardous drug compounding e.g., prevention and control of contamination Unique aspects Radiation protection practices (time, distance, shielding) Supplies: lead shields, absorbent contamination pads Equipment: radioactivity/radiation instruments/monitors

28 Problems Several different definitions of compounding Traditional pharmacy extemporaneous compounding State boards of pharmacy FDA USP Professional organizations, standards of practice Accreditation organizations

29 Problems (cont d) 503A safe harbors for pharmacy compounding do not apply to radiopharmaceuticals. [DQSA 2013] FDA draft guidance document for radiopharmaceutical compounding (12/29/2016) is still undergoing public comment Currently, different interpretations by different inspectors Related issues Nearly 90% radiopharmaceutical doses are prepared in commercial nuclear pharmacies and transported to hospitals and clinics Crossing state lines (e.g., New York City, Washington D.C.) Patient name on each dose

30 Problems (cont d) FDA Draft Guidance for Industry: Insanitary Conditions at Compounding Facilities (Aug 2016) specifically includes compounded or repackaged radiopharmaceuticals The descriptive list of Insanitary Conditions in a Sterile Operation includes several items that may be problematic for radiopharmaceuticals

31 SNMMI White Paper Fall 2016 SNMMI COR developed a white paper entitled USP Public Standards for Compounded Sterile Radiopharmaceuticals: Recommendations from SNMMI Three recommendations from the white paper: Delineate common practices that are defined as sterile compounding within the practice of nuclear pharmacy Create a public standard for the preparation, compounding, and dispensing of sterile radiopharmaceuticals with the practice of nuclear pharmacy [i.e., create a new general chapter] Reinstate an expert committee dedicated to all standards for radiopharmaceuticals [i.e., chapters and monographs] Final_2016.pdf

32 Previous Related Work by USP Radiopharmaceuticals and Medical Imaging Drugs (RMI) Expert Committee proposed, and created a draft of, a new general chapter: <1017> Radiopharmaceutical Quality Assurance and Compounding. But: it was never published in PF; Frank Barletta retired in 2003, the committee turned its focus to PET, and chapter <1206> Sterile Preparations Pharmacy Practices was on its way to becoming <797>

33 Summary Preparation, compounding, and dispensing of sterile radiopharmaceuticals involves unique safety considerations (radiation protection practices) and involves special equipment (lead shielding, radiation detectors) that may necessitate some compromises in aseptic handling practices. A separate USP chapter on Preparation, Compounding, and Dispensing of Sterile Radiopharmaceuticals would serve the profession well in defining and describing standards for these activities, especially in relationship with the FDA Draft Guidance on Compounding and Repackaging of Radiopharmaceuticals

34 USP Stakeholders Workshop on Radiopharmaceutical Compounding Held at USP HQ on Feb 1, 2017 Invited participants included representatives from: Chemical Medicines Monographs 4 Expert Committee Compounding Expert Committee nuclear pharmacists in hospital, commercial, and academic settings FDA SNMMI COR (to present the White Paper) USP staff Most participants endorsed a separate chapter

35 Proposed New General Chapter <825> Compounding - Radiopharmaceuticals The Compounding Expert Committee and USP staff agreed that creation of a new chapter was appropriate Scope and Rationale: Call for candidates for Expert Panel: Very aggressive timeline draft chapter to be published in the Nov-Dec 2018 PF for public comment

36 Key Issues Page: Standards for Radioactive Articles in USP-NF

37 THANK YOU QUESTIONS?

Latest Developments in USP Monographs and the Compounding of Sterile Radiopharmaceuticals. Jim Ponto, MS, RPh, BCNP

Latest Developments in USP Monographs and the Compounding of Sterile Radiopharmaceuticals. Jim Ponto, MS, RPh, BCNP Latest Developments in USP Monographs and the Compounding of Sterile Radiopharmaceuticals Jim Ponto, MS, RPh, BCNP Disclosures Volunteer member on several USP Expert Committees and Expert Panels associated

More information

Role of USP Monographs and. General Chapters. Steve Zigler, Ph.D.

Role of USP Monographs and. General Chapters. Steve Zigler, Ph.D. Role of USP Monographs and General Chapters Steve Zigler, Ph.D. Siemens PETNET Solutions USP Disclosure I have served as a USP volunteer in the area of PET drugs for 15 years Member of various Expert Committees

More information

Paul B Mahan, RPh., BCNP

Paul B Mahan, RPh., BCNP Paul B Mahan, RPh., BCNP Regulatory Affairs department of PETNET Solutions/Siemens Corporation Member of the USP Expert Panel, but not representing the USP organization in this presentation Was

More information

Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>

Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823> Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the

More information

Overview of USP Activities and How to Get Involved

Overview of USP Activities and How to Get Involved Overview of USP Activities and How to Get Involved Ravi Ravichandran, Ph.D. Principal Scientific Liaison, Chemical Medicines United States Pharmacopeia Outline Introduction to the USP USP Standard Setting

More information

Q & A on USP General Chapter <823> Revision Proposal Webinar held on 21 February 2011

Q & A on USP General Chapter <823> Revision Proposal Webinar held on 21 February 2011 1. For day of use calibration, why does the chapter recommend only 2 injections of the known standard versus current standard of 3? Response: The current Chapter does not specify a number of standard

More information

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

USP Chapter 823 USP 32 (old) vs. USP 35 (new) USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has

More information

9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization

9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization USP Monograph Modernization Procedure Review and Development Donald Min 2 USP basic Since USP's founding in 1820, our operations have grown exponentially: from 11 volunteers collaborating from their respective

More information

US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs)

US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs) US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs) 20 th International Symposium Radiopharmaceutical Sciences Jeju, Korea Pre-Symposium Workshop

More information

PET Drug Manufacturing: Living in an FDA-Regulated World

PET Drug Manufacturing: Living in an FDA-Regulated World PET Drug Manufacturing: Living in an FDA-Regulated World June 14, 2016 2:45 4:15 Organizers: Sally W. Schwarz, M.S., R.Ph., BCNP and Steve Zigler, Ph.D. Moderator: Steve Zigler, Ph.D. Sponsors: Radiopharmaceutical

More information

Overview of FDA Regulations and Guidance Documents related to PET Drug Chemistry. Steve Zigler, Ph.D. Siemens PETNET Solutions

Overview of FDA Regulations and Guidance Documents related to PET Drug Chemistry. Steve Zigler, Ph.D. Siemens PETNET Solutions Overview of FDA Regulations and Guidance Documents related to PET Drug Chemistry Steve Zigler, Ph.D. Siemens PETNET Solutions Employee of Siemens-PETNET Solutions I will not discuss investigational agents,

More information

Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding h823i

Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding h823i 2 Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding h823i Joseph C. Hung, PhD, a Sally W. Schwarz, RPh, MS, a,b Steve S. Zigler, PhD, a,c Ravi Ravichandran,

More information

Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey

Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey Important Updates in USP and USP Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey Disclosures Principal-Clinical IQ, LLC Healthcare consulting

More information

for IND and RDRC Regulated PET Compounding

for IND and RDRC Regulated PET Compounding Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada

More information

Pharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD

Pharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD Pharmaceutical Compounding Sterile and Nonsterile Preparations Jeanne Sun, PharmD Agenda Legal Framework Overview Pharmaceutical Compounding Nonsterile Preparations Pharmaceutical Compounding

More information

Best Chemistry Practices to Support the Development of PET Drugs

Best Chemistry Practices to Support the Development of PET Drugs Best Chemistry Practices to Support the Development of PET Drugs June 10, 2017 8:00 16:00 Organizers and Moderators: Amy Vavere, Ph.D. Steve Zigler, Ph.D. Sponsors: Radiopharmaceutical Sciences Council

More information

CGMP Requirements for Investigational Products

CGMP Requirements for Investigational Products PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health

More information

THE INTERNATIONAL PHARMACOPOEIA

THE INTERNATIONAL PHARMACOPOEIA June 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 THE INTERNATIONAL PHARMACOPOEIA RADIOPHARMACEUTICALS:

More information

Bench to Bedside - The Roadmap Chemistry, Manufacturing, and Controls Issues in Radiopharmaceutical Applications

Bench to Bedside - The Roadmap Chemistry, Manufacturing, and Controls Issues in Radiopharmaceutical Applications Bench to Bedside - The Roadmap Chemistry, Manufacturing, and Controls Issues in Radiopharmaceutical Applications 55 th Annual Meeting of the Society of Nuclear Medicine New Orleans, LA, June 14-18, 18,

More information

Overview of Generic PET Applications. Sema Basaran, Ph.D. The 34 th Annual High Country Nuclear Medicine Conference.

Overview of Generic PET Applications. Sema Basaran, Ph.D. The 34 th Annual High Country Nuclear Medicine Conference. Overview of Generic PET Applications Sema Basaran, Ph.D. The 34 th Annual High Country Nuclear Medicine Conference. March 1-6, 2013 Disclaimer This presentation reflects the views of the presenter and

More information

5.19. EXTEMPORANEOUS PREPARATION OF RADIOPHARMACEUTICAL PREPARATIONS

5.19. EXTEMPORANEOUS PREPARATION OF RADIOPHARMACEUTICAL PREPARATIONS Pharmeuropa 26.2 1 Reference: NOTE ON THE GENERAL CHAPTER A first draft of this general chapter was presented in Pharmeuropa 23.4 with the title Compounding of radiopharmaceutical preparations. The chapter

More information

Re: Comments to FDA re Guidance Document on Data Integrity and Compliance with CGMP

Re: Comments to FDA re Guidance Document on Data Integrity and Compliance with CGMP July 19, 2016 Food and Drug Administration 10903 New Hampshire Ave. Silver Spring, Maryland 20993 Re: Comments to FDA re Guidance Document on Data Integrity and Compliance with CGMP The Society of Nuclear

More information

USP Standards for Radiopharmaceuticals

USP Standards for Radiopharmaceuticals USP Standards for Radiopharmaceuticals June 12, 2017 10:00 11:30 Organizers: Ravi Ravichandran, PhD, Jim Ponto, MS, RPh, BCNP, Steve Zigler, PhD Moderator: Ravi Ravichandran, PhD Sponsor: Coalition for

More information

The ABCs and Challenges of GMP The American Experience

The ABCs and Challenges of GMP The American Experience The ABCs and Challenges of GMP The American Experience The Canadian Association of Nuclear Medicine Toronto, Ontario April 22, 2017 Reiko Oyama, R.Ph., B.C.N.P. Washington University School of Medicine

More information

Update to USP <621> Chromatography: What does this mean? USP 37 NF 32 1S Current as of August 2014

Update to USP <621> Chromatography: What does this mean? USP 37 NF 32 1S Current as of August 2014 Update to USP Chromatography: What does this mean? USP 37 NF 32 1S Current as of August 2014 2015 Waters Corporation 1 What is the USP-NF? The United States Pharmacopeia National Formulary (USP-NF)

More information

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES 1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst

More information

Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees

Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities Plus an update on PET Drug User Fees Michael Nazerias - Vice President, RA/QA PETNET Solutions, Inc. (a Siemens Company)

More information

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity

More information

REVISED DRAFT FOR COMMENT

REVISED DRAFT FOR COMMENT March 2014 Document for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 THE INTERNATIONAL PHARMACOPOEIA RADIOPHARMACEUTICALS: SPECIFIC MONOGRAPH

More information

Quality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018

Quality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Quality of raw materials and manufacturing of advanced therapies Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Evolution of the compendia 1820: a single recipe book 2018: Procedures and acceptance

More information

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific

More information

Tracer-QC. 1 Sample 1 Analytical Instrument 10 Tests 1 Traceable & Objective Report. EC-Detector. QC Solutions. Automated optical testing for PET-QC

Tracer-QC. 1 Sample 1 Analytical Instrument 10 Tests 1 Traceable & Objective Report. EC-Detector. QC Solutions. Automated optical testing for PET-QC 1 Sample 1 Analytical Instrument 10 Tests 1 Traceable & Objective Report Life Sciences Service and Support Related Products Users of our systems can benefit from our comprehensive, fully inclusive service

More information

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific

More information

Compounding Animal Drugs From Bulk Drug Substances; Draft Guidance for Industry;

Compounding Animal Drugs From Bulk Drug Substances; Draft Guidance for Industry; This document is scheduled to be published in the Federal Register on 05/19/2015 and available online at http://federalregister.gov/a/2015-11982, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Flexible and Pending Monographs

Flexible and Pending Monographs Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention Flexible Monographs: Background From

More information

Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education

Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education Loyd V. Allen, Jr., Ph.D. Professor & Chair Emeritus University of Oklahoma HSC College of Pharmacy Editor-in in-chief International

More information

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance U.S. Department of Health and Human Services Food and Drug Administration Center for

More information

Guidance PET Drug Products Current Good Manufacturing Practice (CGMP)

Guidance PET Drug Products Current Good Manufacturing Practice (CGMP) Guidance PET Drug Products Current Good Manufacturing Practice (CGMP) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft

More information

Public Assessment Report. Scientific discussion. Fludeoxyglucose ( 18 F) MCA MBq, solution for injection in prefilled syringe

Public Assessment Report. Scientific discussion. Fludeoxyglucose ( 18 F) MCA MBq, solution for injection in prefilled syringe Public Assessment Report Scientific discussion Fludeoxyglucose ( 18 F) CA 100-400 Bq, solution for injection in prefilled syringe (fludeoxyglucose ( 18 F)) NL License RVG: 115336 Date: 17 April 2018 This

More information

Compounding Pharmacy Assessment Questionnaire (CPAQ )

Compounding Pharmacy Assessment Questionnaire (CPAQ ) Compounding Pharmacy Assessment Questionnaire (CPAQ ) The International Academy of Compounding Pharmacists represents more than 2,700 pharmacists and other professionals who specialize in the provision

More information

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4 VOLUME 13 NUMBER 4 Secundum Artem Current & Practical Compounding Information for the Pharmacist. USP Chapter Pharmaceutical Compounding - Nonsterile Preparations GOALS AND OBJECTIVES Goal: The goal

More information

Pharmacy Compounding: Infection Prevention

Pharmacy Compounding: Infection Prevention Pharmacy Compounding: Infection Prevention Sam Eberwein, PharmD, MS, BCPS Clinical Manager, Sterile Products Area, Perioperative Services, & Special Formulations UNC Medical Center Department of Pharmacy

More information

LUNCH AND LEARN. October 14, CE Activity Information & Accreditation

LUNCH AND LEARN. October 14, CE Activity Information & Accreditation LUNCH AND LEARN USP Chapter : What s on the Radar? October 14, 2016 Featured Speaker: Patricia C. Kienle, RPh, MPA, FASHP Director, Accreditation and Medication Safety Cardinal Health Innovative Delivery

More information

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug

More information

Recent USP Updates May, 2013

Recent USP Updates May, 2013 Recent USP Updates May, 2013 Don Singer GSK Bioburden Control of Non-sterile Drug Substances and Products The chapter emphasizes control as a risk mitigation strategy The chapter recommends a risk-based

More information

Commentary Pharmacopeial Forum 35(5) Sept.-Oct Interim Revision Announcements to USP 33-NF 28 Reissue

Commentary Pharmacopeial Forum 35(5) Sept.-Oct Interim Revision Announcements to USP 33-NF 28 Reissue Commentary Pharmacopeial Forum 35(5) Sept.-Oct. 2009 Interim Revision Announcements to USP 33-NF 28 Reissue In accordance with USP s Rules and Procedures of the Council of Experts, USP publishes all proposed

More information

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to

More information

Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances

Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances #230 Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this

More information

Early Development Best Practices for Stability- Regulatory Perspective

Early Development Best Practices for Stability- Regulatory Perspective Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment

More information

Overview. A brief from

Overview. A brief from A brief from Dec 2017 Getty Images What Are Compounded Drugs, and How Can They Be Kept Safe? Drug Quality and Security Act plays key role in important but potentially high-risk aspect of health care Overview

More information

Complies with the monograph for Parenteral Preparations and with that for Radiopharmaceuticals.

Complies with the monograph for Parenteral Preparations and with that for Radiopharmaceuticals. January 2009 THALLOUS ( 201 Tl) CHLORIDE INJECTION: Final text for addition to The International Pharmacopoeia (January 2009) This monograph was adopted at the Forty-third WHO Expert Committee on Specifications

More information

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics

More information

STIMULI TO THE REVISION PROCESS

STIMULI TO THE REVISION PROCESS Page 1 of 6 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts USP's Nomenclature Initiatives Angela G. Long, M.S.; Andrzej

More information

Responding to an FDA 483

Responding to an FDA 483 Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest

More information

Drug Products, Labeling, and Packaging

Drug Products, Labeling, and Packaging 442 Pharmaceutical Industry: Drug Products, Labeling, and Packaging Positions Drug Products, Labeling, and Packaging Ready-to-Administer Packaging for Hazardous Drug Products Intended for Home Use (1711)

More information

USP Priority Excipient Monograph Modernization Updates

USP Priority Excipient Monograph Modernization Updates The USP Excipients Stakeholder Forum Meeting # 2 June 18, 2014 USP Priority Excipient Monograph Modernization Updates Catherine Sheehan Senior Director, Excipients United States Pharmacopeial Convention

More information

THALLOUS ( 201 Tl) CHLORIDE INJECTION: Revised Final text for addition to The International Pharmacopoeia (January September 2009)

THALLOUS ( 201 Tl) CHLORIDE INJECTION: Revised Final text for addition to The International Pharmacopoeia (January September 2009) September 2009 RESTRICTED THALLOUS ( 201 Tl) CHLORIDE INJECTION: Revised Final text for addition to The International Pharmacopoeia (January September 2009) [Note from the Secretariat: This monograph was

More information

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/

More information

Position: Sr. Director of Education and Data - NHIA, VP of Research - NHIF

Position: Sr. Director of Education and Data - NHIA, VP of Research - NHIF Comment Submission Template for: General Chapter Pharmaceutical Compounding Sterile Preparations Revision proposed in Pharmacopeial Forum 41(6) Nov/Dec 2015 Send completed template to CompoundingSL@usp.org

More information

FDA Update on Compounding

FDA Update on Compounding FDA Update on Compounding Julie Dohm, JD, PhD Senior Science Advisor for Compounding, Center for Drug Evaluation and Research; Agency Lead on Compounding, FDA Compounding A Snapshot Compounded drugs: Are

More information

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation 3/22/2012; page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Morphine Sulfate, USP 0.200 g Sodium Chloride, USP 0.152 g Sterile Water For Injection, USP 15.0 ml Sterile Water For

More information

Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations

Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations Source of base information Pharmacopeial Form Vol 29 (4) July Aug. 2003 Effective date January 1, 2004 FDA enforceable Scope The content

More information

I. Purpose. II. Definitions. Last Approval Date

I. Purpose. II. Definitions. Last Approval Date Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics

More information

CURRENT CHALLENGES IN GLOBAL REGULATORY COMPLIANCE QUALITY OF PHARMACEUTICAL INGREDIENTS PHARMACOPOEIAL HARMONISATION PROCESS

CURRENT CHALLENGES IN GLOBAL REGULATORY COMPLIANCE QUALITY OF PHARMACEUTICAL INGREDIENTS PHARMACOPOEIAL HARMONISATION PROCESS CURRENT CHALLENGES IN GLOBAL REGULATORY COMPLIANCE QUALITY OF PHARMACEUTICAL INGREDIENTS PHARMACOPOEIAL HARMONISATION PROCESS Dr. Vinay G Nayak President, Technical Operations Alembic Pharmaceuticals Limited

More information

How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.

How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci. 2017 AAM CMC Workshop How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci. The information within this presentation

More information

Japanese Pharmacopoeia s Challenge to the Globalization

Japanese Pharmacopoeia s Challenge to the Globalization Japanese Pharmacopoeia s Challenge to the Globalization Naoyuki Yabana, Ph.D. Division of Pharmacopoeia and Standards for Drugs, Office of Standards and Guidelines Development, Pharmaceuticals and Agency

More information

Production of radiopharmaceuticals for clinical and research uses

Production of radiopharmaceuticals for clinical and research uses Production of radiopharmaceuticals for clinical and research uses The European perspective Philip Elsinga UMC Groningen The Netherlands The Rules European players in (radio ) pharmaceutical legislation

More information

PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS

PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June

More information

Title: Department: Approved by: Director, Human Research Review and Compliance

Title: Department: Approved by: Director, Human Research Review and Compliance Title: Department: Requirements for Investigational New Drug (IND) for Human- Subjects Research Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners HealthCare

More information

PosiRx. automated radiopharmaceutical system

PosiRx. automated radiopharmaceutical system PosiRx automated radiopharmaceutical system introducing PosiRx : Positron Corporation would like to introduce PosiRx, the future of radiopharmaceutical dose preparation and delivery. PosiRx is a radiopharmaceutical

More information

GMP and Quality Control: An Industry Perspective. Steven S. Zigler, Ph.D. PETNET Pharmaceuticals, Inc. Knoxville, Tennessee

GMP and Quality Control: An Industry Perspective. Steven S. Zigler, Ph.D. PETNET Pharmaceuticals, Inc. Knoxville, Tennessee GMP and Quality Control: An Industry Perspective Steven S. Zigler, Ph.D. PETNET Pharmaceuticals, Inc. Knoxville, Tennessee GMP in Preparation of Precursors Not necessary However, we need stability data

More information

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn. Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities

More information

Industry Perspective on PET Manufacturing Comparison of EU and US

Industry Perspective on PET Manufacturing Comparison of EU and US Standards for Imaging Endpoints and Manufacturing of PET Radiopharmaceuticals Industry Perspective on PET Manufacturing Comparison of EU and US Guidances and associated Regulations Natcher Conference Center

More information

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug

More information

BRIEFING. PF 44(4) [July Aug. 2018]. The General Chapters Packaging and. Distribution Expert Committee has canceled the PF 44(4) proposal and is

BRIEFING. PF 44(4) [July Aug. 2018]. The General Chapters Packaging and. Distribution Expert Committee has canceled the PF 44(4) proposal and is BRIEFING 659 Packaging and Storage Requirements, USP 42 page 6801 and PF 44(4) [July Aug. 2018]. The General Chapters Packaging and Distribution Expert Committee has canceled the PF 44(4) proposal and

More information

Elementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP

Elementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP Elementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP Ludwig Huber, Ph.D Chief Advisor, Global FDA Compliance for Ludwig Huber Phone: +49 7902 980582 E-mail: Ludwig_Huber@Labcompliance.com

More information

Challenges And Opportunities In Developing And Modernizing Public Standards For NF Monographs

Challenges And Opportunities In Developing And Modernizing Public Standards For NF Monographs Excipient Fest Puerto Rico April 28-29, 2015 Challenges And Opportunities In Developing And Modernizing Public Standards For NF Monographs Catherine Sheehan Sr. Director, Excipients United States Pharmacopeial

More information

Method Validation Studies How GLP Interacts With Guidance Documents

Method Validation Studies How GLP Interacts With Guidance Documents Method Validation Studies How GLP Interacts With Guidance Documents Steven S. Kuwahara ROBERT GEORGE YOUNG/GETTY IMAGES GLP Forum addresses topics of interest associated with good laboratory practices.

More information

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017 Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical

More information

Guidance. Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs GUIDANCE

Guidance. Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs GUIDANCE Guidance Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs GUIDANCE U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Re: Insanitary Conditions at Compounding Facilities, Guidance for Industry (Docket ID: FDA-2016-D )

Re: Insanitary Conditions at Compounding Facilities, Guidance for Industry (Docket ID: FDA-2016-D ) Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD 20852 [Submitted electronically to www.regulations.gov]

More information

Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services

Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and

More information

Excipient Stakeholder Forum Updates Stakeholder Forum Progress and Achievements. Steve Boudreau Gelatin Manufacturers Institute of America

Excipient Stakeholder Forum Updates Stakeholder Forum Progress and Achievements. Steve Boudreau Gelatin Manufacturers Institute of America Excipient Stakeholder Forum Updates Stakeholder Forum Progress and Achievements Steve Boudreau Gelatin Manufacturers Institute of America Excipient Stakeholder Forum Purpose Overarching Purpose To provide

More information

Radiopharmaceuticals overview of requirements

Radiopharmaceuticals overview of requirements Radiopharmaceuticals overview of requirements Did you know? That Australia has a research nuclear reactor producing nuclear medicine 1 in 2 Australians will receive some kind of nuclear medicine in their

More information

MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS

MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community

More information

September 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

September 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim

More information

Nonsterile Compounding: USP and Best Practices for Community Pharmacists

Nonsterile Compounding: USP and Best Practices for Community Pharmacists Nonsterile Compounding: USP and Best Practices for Community Pharmacists Target Audience: Pharmacists and Pharmacy Technicians ACPE#: 0202-0000-18-033-L07-P/T Activity Type: Knowledge-based Disclosures

More information

THE USE OF NON-PHARMACEUTICAL GRADE SUBSTANCES IN THE UA ANIMAL CARE & USE PROGRAM

THE USE OF NON-PHARMACEUTICAL GRADE SUBSTANCES IN THE UA ANIMAL CARE & USE PROGRAM THE USE OF NON-PHARMACEUTICAL GRADE SUBSTANCES IN THE UA ANIMAL CARE & USE PROGRAM POLICY: This policy provides a definitive position on the use of non-pharmaceutical grade substances in the UA animal

More information

Washington State University INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE

Washington State University INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE Washington State University INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE Use of Non-Pharmaceutical Grade Substances and Compounding Drugs in Laboratory Animals Purpose: To prevent contamination, infection

More information

á232ñ ELEMENTAL IMPURITIES LIMITS

á232ñ ELEMENTAL IMPURITIES LIMITS First Supplement to USP 40 NF 35 Chemical Tests / á232ñ al Impurities Limits 8065 Standard Solution Table 10 (Continued) of Neu5Ac after Labeling (mm) of Neu5Gc after Labeling (mm) 4 0.2 0.01 5 0.4 0.02

More information

AMENDED Draft Report of the Compounding Workgroup

AMENDED Draft Report of the Compounding Workgroup AMENDED Draft Report of the Compounding Workgroup This report summarizes the actions taken by a workgroup convened by the Board of Pharmacy pursuant to the enactment clause of HB 1035 passed during the

More information

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review

Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical

More information

A.1 Contents file 4 to 5 A.1 (1)

A.1 Contents file 4 to 5 A.1 (1) Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW

More information

European Medicines Agency Inspections

European Medicines Agency Inspections European Medicines Agency Inspections London, 31 March 2006 CHMP/QWP/185401/2004 final COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE REQUIREMENTS TO THE CHEMICAL AND PHARMACEUTICAL

More information

Orange and Yellow Guides

Orange and Yellow Guides PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING FIELD? Dr. Alison M.Beaney Regional Quality Assurance Specialist North-East England PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING

More information

CANADA (HEALTH CANADA)

CANADA (HEALTH CANADA) 1 GMP GAZETTE TM March 2015 HPFBI CANADA (HEALTH CANADA) Notice, Re: Regulatory Decision Summaries and Submissions Under Review Who s affected? Manufacturers of prescription drugs (pharmaceuticals and

More information

United State Pharmacopeia: Compendial Plastic Standards: Beyond Packaging

United State Pharmacopeia: Compendial Plastic Standards: Beyond Packaging United State Pharmacopeia: Compendial Plastic Standards: Beyond Packaging Desmond G. Hunt, Ph.D. Principle Scientific Liaison November 15, 2016 Denver, CO USP Scientific, independent, volunteer-driven,

More information

Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC

Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC U.S. House of Representatives Energy and Commerce Committee Subcommittee on Health Subcommittee January 30, 2018

More information

Ge / 68 Ga GENERATOR* HOW TO DO PET AS SIMPLY AS SPECT? EXCELLENCE DEDICATED TO NUCLEAR MEDICINE, HEALTHCARE & ENVIRONMENT

Ge / 68 Ga GENERATOR* HOW TO DO PET AS SIMPLY AS SPECT? EXCELLENCE DEDICATED TO NUCLEAR MEDICINE, HEALTHCARE & ENVIRONMENT 68 Ge / 68 Ga GENERATOR* HOW TO DO PET AS SIMPLY AS SPECT? EXCELLENCE DEDICATED TO NUCLEAR MEDICINE, HEALTHCARE & ENVIRONMENT * In the European Union, Galli Eo is chemical grade dedicated for research

More information

Draft Guidelines for Radiopharmacy

Draft Guidelines for Radiopharmacy Draft Guidelines for Radiopharmacy In the nuclear medicine laboratories (radiopharmacies) of nuclear medicine clinics in European hospitals, quality assurance varies from non-existent to good manufacturing

More information